The latest content updates from the drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ http://www.drugdevelopment-technology.com/content/images/logo_big.gif http://www.drugdevelopment-technology.com/news/newsipsen-reports-q4-and-full-year-2011-sales http://www.drugdevelopment-technology.com/news/newsipsen-reports-q4-and-full-year-2011-sales Ipsen, a global specialty-driven pharmaceutical company, has reported its fourth quarter and full year results with total sales exceeding €1.1bn in 2011. Fri, 03 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsobd-drug-meets-phase-3-trial-primary-endpoint-sucampo-takeda http://www.drugdevelopment-technology.com/news/newsobd-drug-meets-phase-3-trial-primary-endpoint-sucampo-takeda Sucampo Pharmaceuticals (SPI) and Takeda Pharmaceuticals have announced the results from the Phase 3 clinical trial of lubiprostone as a treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those ta… Fri, 03 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsmdv3100-shows-efficacy-against-prostate-cancer http://www.drugdevelopment-technology.com/news/newsmdv3100-shows-efficacy-against-prostate-cancer Medivation and Astellas Pharma have announced the positive results from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy. Thu, 02 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsnovartis-glivec-wins-extended-fda-approval-for-three-year-treatment http://www.drugdevelopment-technology.com/news/newsnovartis-glivec-wins-extended-fda-approval-for-three-year-treatment The Novartis Glivec (imatinib) label has received an extended approval by the US Food and Drug Administration (FDA) to recommend 36 months of treatment for adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST). Thu, 02 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/features/featureless-is-more-why-rare-disease-funding-is-on-the-up/ http://www.drugdevelopment-technology.com/features/featureless-is-more-why-rare-disease-funding-is-on-the-up/ Despite reductions in R&D spending, clinical trials for rare diseases are going full steam ahead. Elly Earls speaks to Alastair Kent of Genetic Alliance UK, Tim Cote of the National Organization for Rare Disorders (NORD) and Dr Steve Groft of the Off… Thu, 02 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsargos-reports-ags-003-combination-therapy-trial-data http://www.drugdevelopment-technology.com/news/newsargos-reports-ags-003-combination-therapy-trial-data Argos Therapeutics' Arcelis immunotherapy, AGS-003, in combination with sunitinib has showed a correlation between anti-tumour memory T cell responses and overall survival in Phase 2 study in patients with advanced renal cell carcinoma (RCC). Wed, 01 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsboehringer-eli-lilly-diabetes-drug-wins-fda-nod http://www.drugdevelopment-technology.com/news/newsboehringer-eli-lilly-diabetes-drug-wins-fda-nod Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced that the US Food and Drug Administration (FDA) has approved Jentadueto (linagliptin / metformin hydrochloride) tablets, used for treating adults with type 2 diabetes. Wed, 01 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/projects/provenge-for-the-treatment-of-advanced-prostate-cancer/ http://www.drugdevelopment-technology.com/projects/provenge-for-the-treatment-of-advanced-prostate-cancer/ Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate cancer. Wed, 01 Feb 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsallos-therapeutics-reports-interim-data-of-folotyn-combination-therapy http://www.drugdevelopment-technology.com/news/newsallos-therapeutics-reports-interim-data-of-folotyn-combination-therapy Allos Therapeutics has announced the interim results from the ongoing Phase 1 combination study of Folotyn (pralatrexate injection) and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Tue, 31 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsfda-clears-pfizer-inlyta-for-kidney-cancer http://www.drugdevelopment-technology.com/news/newsfda-clears-pfizer-inlyta-for-kidney-cancer The US Food and Drug Administration (FDA) has approved Pfizer's Inlyta (axitinib), a kinase inhibitor, intended for treating patients with advanced renal cell carcinoma (RCC) following failure of one prior systemic therapy. Tue, 31 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsamylin-alkermes-diabetes-drug-wins-fda-approval http://www.drugdevelopment-technology.com/news/newsamylin-alkermes-diabetes-drug-wins-fda-approval Amylin Pharmaceuticals and Alkermes have announced that the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. Mon, 30 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsmillennium-announces-phase-i-trial-data-of-adcetris http://www.drugdevelopment-technology.com/news/newsmillennium-announces-phase-i-trial-data-of-adcetris Millennium, part of the Takeda Group, has announced the interim results from a Phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination with or sequentially with chemotherapy to treat newly diagnosed systemic anaplastic la… Mon, 30 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsbiogen-idec-elan-begins-multiple-sclerosis-drug-study http://www.drugdevelopment-technology.com/news/newsbiogen-idec-elan-begins-multiple-sclerosis-drug-study Biogen Idec and Elan Corporation are conducting a global Phase 3b study, designed to evaluate the effectiveness of Tysabri as a treatment for secondary-progressive multiple sclerosis (SPMS). Fri, 27 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newschimerix-reports-phase-2-trial-data-of-cmx001 http://www.drugdevelopment-technology.com/news/newschimerix-reports-phase-2-trial-data-of-cmx001 Chimerix, a biotechnology company developing novel antiviral therapeutics, has announced the final data from Phase II study 201 evaluating CMX001 for the prevention of cytomegalovirus (CMV). Fri, 27 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsmerck-serono-introduces-rebif-in-uk http://www.drugdevelopment-technology.com/news/newsmerck-serono-introduces-rebif-in-uk Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has introduced Rebif (interferon beta-1a) in the UK to treat people who have experienced clinically isolated syndrome (CIS), an early sign of multiple sclerosis (MS). Thu, 26 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsadvaxis-reports-safety-and-survival-data-of-cancer-drug http://www.drugdevelopment-technology.com/news/newsadvaxis-reports-safety-and-survival-data-of-cancer-drug Advaxis has reported the preliminary data on the safety and clinical benefit of ADXS-HPV with or without cisplatin in Indian women with recurrent / refractory cervical cancer who have failed cytotoxic therapy from an ongoing randomised Phase II trial… Thu, 26 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/contractors/sterilisation/priorclave-autoclave/pressvacuum-autoclave-stand-off-legs.html http://www.drugdevelopment-technology.com/contractors/sterilisation/priorclave-autoclave/pressvacuum-autoclave-stand-off-legs.html Priorclave's Compact C40 vacuum autoclave is the first priorclave to become available with stand-off legs, providing easy access beneath the steam steriliser for cleaning and disinfection of laboratory work surfaces. Wed, 25 Jan 2012 15:38:00 GMT http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-9/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-9/ In this issue we investigate how rapidly evolving drug delivery methods are helping to make medicines more effective. Wed, 25 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsgilead-begins-phase-2-study-of-hiv-drug http://www.drugdevelopment-technology.com/news/newsgilead-begins-phase-2-study-of-hiv-drug Gilead Sciences has begun a Phase II clinical trial of its GS-7340 drug, used as a treatment for HIV-1 infection in treatment-naive adults. Wed, 25 Jan 2012 00:00:00 GMT http://www.drugdevelopment-technology.com/news/newsventirx-announces-positive-tlr8-agonist-preclinical-data http://www.drugdevelopment-technology.com/news/newsventirx-announces-positive-tlr8-agonist-preclinical-data VentiRx Pharmaceuticals has announced preclinical data demonstrating that VTX-2337, the company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. Wed, 25 Jan 2012 00:00:00 GMT